Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RLMD |
---|---|---|
09:32 ET | 787 | 3.39 |
09:38 ET | 1000 | 3.492 |
09:41 ET | 300 | 3.45 |
09:52 ET | 1049 | 3.365831 |
09:54 ET | 200 | 3.4323 |
09:56 ET | 100 | 3.4 |
09:57 ET | 100 | 3.4 |
09:59 ET | 2000 | 3.35 |
10:03 ET | 100 | 3.345 |
10:12 ET | 600 | 3.35 |
10:14 ET | 773 | 3.335 |
10:15 ET | 600 | 3.355 |
10:17 ET | 100 | 3.3521 |
10:21 ET | 1894 | 3.31 |
10:24 ET | 17238 | 3.29 |
10:26 ET | 1100 | 3.25 |
10:28 ET | 3840 | 3.28 |
10:30 ET | 910 | 3.29 |
10:32 ET | 121 | 3.29 |
10:33 ET | 100 | 3.28 |
10:35 ET | 900 | 3.33 |
10:48 ET | 277 | 3.3026 |
11:00 ET | 275 | 3.29 |
11:08 ET | 1800 | 3.278 |
11:09 ET | 2200 | 3.274 |
11:13 ET | 200 | 3.31 |
11:15 ET | 200 | 3.33 |
11:18 ET | 100 | 3.35 |
11:20 ET | 2479 | 3.355 |
11:22 ET | 200 | 3.35 |
11:24 ET | 100 | 3.37 |
11:36 ET | 200 | 3.3336 |
11:40 ET | 12900 | 3.28 |
11:44 ET | 1003 | 3.3 |
11:47 ET | 500 | 3.3 |
11:49 ET | 800 | 3.3 |
11:54 ET | 300 | 3.3 |
12:00 ET | 3771 | 3.29 |
12:02 ET | 300 | 3.276 |
12:05 ET | 100 | 3.28 |
12:07 ET | 620 | 3.28 |
12:09 ET | 200 | 3.28 |
12:12 ET | 2859 | 3.2646 |
12:14 ET | 287 | 3.26 |
12:18 ET | 109 | 3.25 |
12:20 ET | 1587 | 3.23 |
12:21 ET | 100 | 3.235 |
12:23 ET | 696 | 3.23 |
12:27 ET | 200 | 3.24 |
12:30 ET | 279 | 3.2706 |
12:34 ET | 200 | 3.265 |
12:36 ET | 400 | 3.2747 |
12:38 ET | 200 | 3.27 |
12:39 ET | 200 | 3.26 |
12:41 ET | 400 | 3.265 |
12:45 ET | 250 | 3.2668 |
12:48 ET | 200 | 3.249 |
12:56 ET | 698 | 3.2613 |
01:03 ET | 100 | 3.26 |
01:12 ET | 100 | 3.234 |
01:14 ET | 400 | 3.25 |
01:15 ET | 7022 | 3.295 |
01:17 ET | 100 | 3.29 |
01:19 ET | 4322 | 3.26 |
01:21 ET | 600 | 3.3 |
01:24 ET | 6171 | 3.25 |
01:30 ET | 122 | 3.2788 |
01:32 ET | 400 | 3.27 |
01:33 ET | 100 | 3.27 |
01:42 ET | 200 | 3.252 |
01:50 ET | 300 | 3.2684 |
01:51 ET | 100 | 3.29 |
01:55 ET | 300 | 3.27 |
02:00 ET | 100 | 3.27 |
02:11 ET | 200 | 3.26 |
02:13 ET | 100 | 3.28 |
02:24 ET | 187 | 3.26 |
02:29 ET | 100 | 3.26 |
02:33 ET | 100 | 3.26 |
02:38 ET | 200 | 3.222 |
02:40 ET | 200 | 3.22 |
02:44 ET | 1000 | 3.244 |
02:47 ET | 100 | 3.26 |
02:56 ET | 393 | 3.3 |
03:02 ET | 200 | 3.29 |
03:03 ET | 100 | 3.3 |
03:05 ET | 525 | 3.3 |
03:09 ET | 1167 | 3.3 |
03:12 ET | 200 | 3.29 |
03:14 ET | 300 | 3.29 |
03:20 ET | 163 | 3.285 |
03:23 ET | 200 | 3.28 |
03:25 ET | 200 | 3.2601 |
03:27 ET | 100 | 3.2608 |
03:32 ET | 300 | 3.25 |
03:36 ET | 400 | 3.25 |
03:45 ET | 100 | 3.25 |
03:52 ET | 359 | 3.262 |
03:54 ET | 100 | 3.262 |
03:57 ET | 315 | 3.28 |
03:59 ET | 3644 | 3.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Relmada Therapeutics Inc | 99.0M | -1.1x | --- |
ALX Oncology Holdings Inc | 98.5M | -0.5x | --- |
Leap Therapeutics Inc | 100.6M | -1.3x | --- |
Eledon Pharmaceuticals Inc | 100.7M | -1.0x | --- |
Checkpoint Therapeutics Inc | 100.4M | -1.5x | --- |
InflaRx NV | 90.7M | -1.7x | --- |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $99.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.51 |
EPS | $-2.88 |
Book Value | $2.84 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.